Novartis announced plans to build a fourth US radioligand therapy manufacturing facility in Winter Park, Florida, as part of ...

Researchers at CSH Laboratory identified an oncogenic SRSF1–AURKA–MYC circuit driving pancreatic ductal adenocarcinoma.

Researchers at the Johns Hopkins KCC have developed a TRBC2-targeted antibody-drug conjugate for T-cell lymphomas and leukemias, addressing half of patients previously lacking precision options. The ...

The FDA has approved RYBREVANT FASPRO, the first subcutaneous amivantamab, for EGFR-mutated NSCLC, enabling five-minute administration with fewer infusion reactions. In Phase III PALOMA-3, ...

The Phase 3 EV-304 KEYNOTE-B15 trial showed that perioperative enfortumab vedotin (PADCEV) plus pembrolizumab (Keytruda) significantly improved event-free survival and overall survival versus ...

Real-world data from nearly 400 patients with advanced, unresectable melanoma show that a flipped, lower-dose ipilimumab regimen increased objective response rates from 37% to 49%, tripled median ...

FDA has approved AKEEGA (niraparib and abiraterone) as the first precision therapy for BRCA2+ metastatic castration-sensitive prostate cancer (mCSPC), following results from the Phase 3 AMPLITUDE ...

An international PANORAMA study shows that artificial intelligence (AI) can outperform radiologists in detecting pancreatic cancer on routine CT scans. Across 3,440 patients, AI achieved an AUROC of 0 ...

Preoperative radiation boosted antitumor immunity and treatment response in HR positive, HER2 negative breast cancer in the phase II P RAD trial presented at SABCS 2025. When combined with ...

GSK’s B7-H3 targeted antibody drug conjugate risvutatug rezetecan has received FDA Orphan Drug Designation for small cell lung cancer, supported by early ARTEMIS 001 data showing durable responses in ...

The results from the Phase 3 HER2CLIMB-05 study, demonstrated that tucatinib added to trastuzumab and pertuzumab in first-line maintenance significantly prolonged progression-free survival in ...

One in four patients with HR+ HER2- metastatic breast cancer remained progression free for at least four years with Kisqali plus endocrine therapy, according to MONALEESA data presented at SABCS 2025.